This case report provides the first evidence that levosimendan can be successfully used to treat acute heart failure in peripartum cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May support levosimendan in peripartum cardiomyopathy shock; hypothesis-generating pending controlled trials.
UNLABELLED: This case represents the first reported use of levosimendan, a calcium-sensitizing drug with additional vasodilation properties, for treatment of a woman with peripartum cardiomyopathy. Levosimendan induced a steady decline of increased pulmonary capillary wedge pressure, followed by a definitive increase in cardiac stroke volume. The patient recovered from this serious episode of heart failure, and she ultimately regained left ventricular function. IMPLICATIONS: Acute heart failure is a life-threatening event that only rarely occurs during childbirth. We report a case of a woman who experienced cardiovascular collapse during vaginal delivery. We determined that she met current diagnostic criteria for peripartum cardiomyopathy, and we successfully treated her with levosimendan, a calcium-sensitizing drug with additional vasodilation properties.
No takes yet. Share an insight, caveat, or question.
Benlolo et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: